

DATE- 13/03/24

NAME - PRAMOD VATICA

AGE/GENDER - S8 /MALE

EMAIL -

PHONE - 9811300753

ADDRESS - HOUSE NO 3171 /2 NOR FOOR

CORPORATE NAME -

1. Past medical history & medications:-

·DUT

2. Any existing disease: -

HIGH BP

3. Current medications :-

4. VITALS - (To be filled by medical personnel)

- BLOOD PRESSURE 115/82 Mmg PULSE RATE 6.4 M
- TEMPERATURE 97.5C
- · SPO2 .9.8.1.
- BLOOD SUGAR (RANDOM) ......
- · HEIGHT 17.4 CM.
- WEIGHT ...... 6 K.9.
- · BMI .. 24.3

VISION- RE-6/20

LE-6/22

Colores vision- Normal.



# 5. FINDINGS: -

LABINVESTIGATION: - All given invertigations Normal.

CARDIOLOGY INVESTIGATIONS: - ECG - NOnma)

RADIOLOGY INVESTIGATIONS: - CXR- few small calcified Hilam Nodes.

6. DOCTOR REMARKS: -

None.





# **ECHOCARDIOGRAPHY REPORT**

Patient's Name	MR PRAMOD VATSA	Date	13-03-2024
Referred by	HEALTH CHECK UP	Age &Sex	58Yrs/M

# MITRAL VALVE

Morphology

AML - Normal / Thickening/Calcification/ Flutter/ Vegetation/ Prolapse/ SAM/ Doming

PML - Normal/ Thickening/ Calcification/ Mild Prolapse/ Paradoxical motion/ fixed.

Sub valvular deformity Present/ Absent

Score: .....

Doppler

Normal/Abnormal

E>A A>E

RR interval.....msec

Mitral Stenosis EDG.....mmHg

Present/Absent MDG.....mmHg

MVA.....cm<sup>2</sup>

Mitral Regurgitation

Absent /Trivial/Mild/Moderate/Severe

### TRICUSPID VALVE

Morphology Doppler

Normal/ Atresia/Thickening/ Calcification/ Prolapse/ Vegetation/ Doming

Normal/ Abnormal

Tricuspid Stenosis

Present/ Absent

RR interval.....

EDG.....mmHg

MDG.....mmHg

Tricuspid Regurgitation: Absent/ Trivial/ Mild/ Moderate/ Severe Fragmented signals

Velocity.....m/sec

### **PULMONARY VALVE**

Morphology

Normal/ Atresia/ Thickening/ Doming/ Vegetation

Doppler

Normal/ Abnormal

Pulmonary Stenosis

Present/Absent

Level Valvular and Sub valvular

PV Max = 1.1 m/sec

PSG.....mmHg Pulmonary annulus.....mm

Pulmonary Regurgitation

Present/ Absent

Early diastolic gradient.....mmHg.

End Diastolic Gradient.....mmHg

## **AORTIC VALVE**

Morphology

Normal/ Thickening/ Tip Calcification/ Restricted Opening/ Flutter vegetation

No. of cusps

1/2/3/4

Doppler

Normal/ Abnormal

Aortic Stenosis: Present/Absent

AV Max = 1.47 m/sec

Aortic Annulus.....mm

Aortic Regurgitation

Absent/ Trivial/ Mild/Moderate/ Severe



Measurements	Normal Values	<u>Measurements</u>	Normal Values Sohna I
Aorta- 2.7 LVes- 2.6 IVSed-1.0 RV ed LVVd (ml) EF 60-65 %	(2.0-3.7 cm) (2.2-4.0 cm) (0.6-1.1 cm) (0.7-2.6 cm) (54%-76%)	LAes- 3.5 LVed- 4.1 PW (LV) 0.7 RV anterior wall LVVs (ml) IVS motion	(1.9-4.0 cm) (3.7-5.6 cm) (0.6-1.1 cm) (up to 5 mm) Normal/ Flat/ Paradoxical

# **CHAMBERS**:

LV <u>Normal</u> / Enlarged/ Clear/ Thrombus/hypertrophy Contraction <u>Normal</u> / Reduced

LA <u>Normal</u>/ Enlarged/ <u>Clear</u>/ Thrombus

RA <u>Normal</u>/ Enlarged/ <u>Clear</u>/ Thrombus

RV <u>Normal/</u> Enlarged/ <u>Clear/</u> Thrombus


Pericardium Normal/ Thickening/ Calcification/ Effusion

# **COMMENTS AND SUMMARY**


- ALL FOUR CHAMBERS NORMAL IS SIZE AND SHAPE
- ALL FOUR VALVES NORMAL IN MORPHOLOGY
- NO MR/AR/TR
- NO AORTIC STENOSIS
- NORMAL LV DIASTOLIC FUNCTION
- NO CLOT/MASS/PE SEEN
- NORMAL LV SYSTOLIC FUNCTION, LVEF= 60-65%

Kindly correlate clinically

DR. RÖHIT GOEL M.D, D.M (Cardiology)







HR 57 bpm RR 1051 ms Sinus thythm PR 146 m Nonmal electron avers. Nonmal alectron avers. Nonmal a	7 bpm RR 1051 ms Sinus rhythm 98 ms Normal electrical ax Normal electrical ax 95 ms 91 ms Normal electrical ax Normal electrical electr	AT-102 G2 1:2 0 (1080:009830) SCHILLER_	25 mm/s, 10 mm/mV	25 mm/s, 10 mm/mV	aVF	avL avL	aVR	Remark	Date of birth - Visit ID  Gender Male Room Height Medication Weight Order ID Ethnicity Undefined Ord. prov. Pacemaker Unknown Ord. prot. Indication	
951 ms 98 ms Noormal electrical axis Noorspecific ST abnormal ECC 402 ms Unconfirmed report  V V V V V V V V V V V V V V V V V V	95 ms Normal electrical axis 95 ms Normal electrical axis 96 ms Nonspecific ST almormality (elevation) 97 ms Otherwise normal ECC 97 ms Unconfirmed report 98 ms V4	Printed on 13 03 202		Sequentia	. V3	W2	V <sub>1</sub>	Otherwise no	0° 47° 48°	
Sinus rhythm Normal electrical axis Nonspecific ST abnorr Otherwise normal ECC Unconfirmed report	Sinus rhythm Normal electrical axis Nonspecific ST abnormality (elevation) Otherwise normal ECC Unconfirmed report  V4  V5  V5  Part No.2.157048M	24 09:26:15						ormal		
		Part			\(\frac{1}{6}\)	\(\sigma_{\sigma}\)	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		Sinus rhythm  Normal electrical axis  Nonspecific ST abnormalit  Otherwise normal ECG  Unconfirmed report	



Patient's Name:- MR. PARMOD

:- 13/03/2024

Referred By :-

**VATS HEALTH CHEAKUP** 

Age/Sex :- 58Y/M

# Radiograph of Chest (PA View)

Prominent broncho vascular marking are seen in bilateral lung fields.

Prominence bilateral hila are seen with few small calcified hilar lymph nodes.

Both CP Angle are clear.

Domes are normally placed.

Cardiac shadow appears normal.

Trachea and mediastinum are normal.

Mild degenerative changes are seen in visualised spine..

Please correlate clinically

Dr Arushi Gupta

MBBS, DNB (Radio - Diagnosis)

Radiologist



# CERTIFICATE OF MEDICAL FITNESS

SIL	is	T
•	Medically Fit	
0	Fit with restrictions/recommendations	
	Though following restrictions have been revealed, in my opinion, these are not impediments to the job.	
	1	
	2	
	3	
	However the employee should follow the advice/medication that has been communicated to him/her.	
	Review after	
0	Currently Unfit.  Review after recommended	
0	Unfit	

This certificate is not meant for medico-legal purposes

# DR. BINDU BISHT

B.D.S, MIDA, MISDT (General Dentist)



	NAME:-	Promod	Vats AG	GE/SEX: 5	8/M	DATE:	March 13 24,
((	)	Throng	h he	alth	check	of.	
0/8	' <i>→</i>	dr. cur	you Vical the	- Gh	ghiods	.7 lo	calded perbobi
Achi	J. 7	-> Cl					

Balley



Patient's Name	MR PRAMOD VATSA	Date	17-03-2024
Referred By	P. M. H. C.	Age/Sex	58YRS/M

# **ULTRASOUND OF ABDOMEN & PELVIS**

# Clinical profile: - HEALTH CHECKUP

**Liver:** , is normal in size, outline and parenchymal echotexture . No focal lesion is seen. There is no evidence of intrahepatic biliary dilatation. The hepatic veins are normal. The portal vein shows normal flow and appears normal in calibre.

**GALL BLADDER:** is well distended. No calculus or mass is seen. Visualized portion of CBD is normal in calibre.

PANCREAS: Normal in size, shape and echo pattern. Main pancreatic diameter is normal.

SPLEEN: Normal in size shape and echopattern. No focal lesion is seen.

KIDNEYS- Both kidneys are normal in size, shape, position, axis and echopattern.

The corticomedullary differentiation is well maintained. A 12mm simple cortical cyst is seen towards upper pole on right side

No calculus or hydronephrosis is seen on either side..

URINARY BLADDER shows mild irregularity of the outline. No calculus/mass seen.

PROSTATE: is enlarged. It measures 53x46x43mm and weighs 56gms.

The prevoid urinary bladder is 173cc. the residual urine is 21cc

No free fluid is seen in abdominal cavity. No e/o any lymphadenopathy.

IMPRESSION:

FEATURES OF MILD CYSTITIS

PROSTATOMEGALY.

CLINICAL CORRELATION IS NECESSARY

DR. RAJNISH JUNEJA

MBBS, DNB RADIODIAGNOSIS









Age/Gender : 58 Y O M O D /M

: SELF

LabNo : DPL22065

Referred BY

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:50PM

# DEPARTMENT OF HAEMATOLOGY APOLLO PACKAGE 2

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE BLOOD COUNT				
Sample Type: WHOLE BLOOD EDTA				
HAEMOGLOBIN (HB)	14.40	gm/dL	13.5 - 18.0	Cynmeth Photometric Measurement
RBC COUNT(RED BLOOD CELL COUNT)	4.6	mil/cu.mm	4.7 - 6.0	Electrical Impedence
PCV/HAEMATOCRIT	42.7	%	42-52	Calculated
MCV	93.30	fL	78-100	Electrical Impedence
MCH	31.5	pg	27-31	Calculated
MCHC	33.7	gm/dL	32-36	Calculated
RDW-SD	13.0	fL	39-46	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	4780	cell/cmm	4000-10000	Electrical Impedence
NEUTROPHIL	50	%	40-80	VCSn Technology
LYMPHOCYTE	37	%	20-40	VCSn Technology
MONOCYTE	10	%	2-10	VCSn Technology
EOSINOPHIL	03	%	1-6	VCSn Technology
BASOPHIL	00	%	0-2	VCSn Technology
PLATELET COUNT	182	10^3/ul	150 - 450	Electrical Impedence
MPV	11.7	fL	7.2 - 11.7	Electrical Impedence
PCT	0.2	%	0.2 - 0.5	Calculated
PDW	14.1	%	9.0 - 17.0	Calculated
ABSOLUTE NEUTROPHIL COUNT	2.39	x10^3 Cells/uL	1.5-7.8	<b>Automated Calculated</b>
ABSOLUTE LYMPHOCYTE COUNT	1.77	x10^3 Cells/uL	2.0-3.9	<b>Automated Calculated</b>
ABSOLUTE MONOCYTE COUNT	0.48	x10^3 Cells/uL	0.2-0.95	<b>Automated Calculated</b>
ABSOLUTE EOSINOPHIL COUNT	0.14	x10^3 Cells/uL	0.2-0.5	<b>Automated Calculated</b>

Tests done on Automated Three Part Cell Counter. (WBC, RBC,Platelet count by impedance method, colorimetric method for Hemoglobin, WBC differential by flow cytometry using laser technology other parameters are calculated). All Abnormal Haemograms are reviewed confirmed microscopically.





Patient NAME

: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo Referred BY : DPL22065

Refer Lab/Hosp

: SELF : APOLLO CLINIC Barcode NO

: 20010614

Registration Date

: 13/Mar/2024 12:59PM

Sample Collected Date

: 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:50PM

# **DEPARTMENT OF HAEMATOLOGY APOLLO PACKAGE 2**

Test Name	Result	Unit	Bio. Ref. Range	Method
ERYTHROCYTE SEDIMENTATION RATE				
Sample Type : WHOLE BLOOD EDTA				
ERYTHROCYTE SEDIMENTATION RATE	19	mm/hr	<20	EDTA Whole blood, modified westerngren

## Note:

- 1. Test conducted on EDTA whole blood at 37°C.
- 2. ESR readings are auto- corrected with respect to Hematocrit (PCV) values.
- 3. It indicates presence and intensity of an inflammatory process. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, acute rheumatic fever. It is also increased in multiple myeloma, hypothyroidism.





Patient NAME

: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo

: DPL22065

Referred BY Refer Lab/Hosp : SELF

: APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 03:35PM

# DEPARTMENT OF HAEMATOLOGY APOLLO PACKAGE 2

Test Name

Result

Unit

Bio. Ref. Range

Method

**BLOOD GROUP ABO & RH** 

Sample Type: WHOLE BLOOD EDTA

ABO

"B"

Gel Columns agglutination

POSITIVE

Gel agglutination

COMMENTS:

Rh Typing

The test will detect common blood grouping system A, B, O, AB and Rhesus (RhD). Unusual blood groups or rare subtypes will not be detected by this method. Further investigation by a blood transfusion laboratory, will be necessary to identify such groups.

**Disclaimer:** There is no trackable record of previous ABO & RH test for this patient in this lab. Please correlate with previous blood group findings.





: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065

Referred BY

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

	AI OL	LO I ACKAGE Z		
Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST				
Sample Type : SERUM				
TOTAL BILIRUBIN	0.69	mg/dL	0.1-1.2	Jendrassik Grof
CONJUGATED ( D. Bilirubin)	0.20	mg/dL	Adults and Children: < 0.3	Diazotization
UNCONJUGATED (I.D. Bilirubin)	0.49	mg/dL	0.1 - 1.0	Calculated
SGPT	21.50	U/L	< 45	UV with P5P, IFCC 37 Degree
SGOT	20.80	U/L	< 50	UV with P5P, IFCC 37 degree
SGOT/SGPT	0.97	Ratio	0.7 - 1.4	· ·
GGT	22	U/L	< 55	G-glutamyl-carboxy- nitoanilide
ALKALINE PHOSPHATASE	89.00	U/L	56-119	PNPP, AMP Buffer, IFCC 37 degree
TOTAL PROTEINS	7.20	g/dL	6.6-8.3	Biuret, reagent blank end point
ALBUMIN	4.10	g/dL	Adults: 3.5 - 5.2	Bromcresol purple
GLOBULIN	3.1	g/dL	1.8 - 3.6	Calculated
A/G RATIO	1.32	Ratio	1.2 - 2.2	Calculated

#### Note:

#### **Bilirubin Total**

Clinical Significance: "Total Bilirubin is one of the most commonly used tests to assess liver function. A number of inherited and acquired diseases affect bilirubin production, metabolism, storage and excretion and causes hyperbilirubinemia resulting in jaundice. Hyperbilirubinemia may be due to increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Unconjugated hyperbilirubinemia is seen in newborn andd known as physiological jaundice. Elevated unconjugated bilirubin in the neonatal period may result in brain damage (kernicterus). Crigler-Najjar syndromes type I and type II are also associated with elevated levels of indirect bilirubin. Both conjugated and unconjugated bilirubin are increased in hepatitis and space-occupying lesions of the liver; and obstructive lesions such as carcinoma of the head of the pancreas, common bile duct, or ampulla of Vater."

#### **Bilirubin Direct**

Clinical Significance: "Direct bilirubin is a measurement of conjugated bilirubin. Jaundice can occur as a result of increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Inherited disorders in which direct bilirubin levels are increased are seen in Dubin-Johnson syndrome and Rotor syndrome, idiopathic neonatal hepatitis and biliary atresia. The most commonly occurring form of jaundice of the newborn called physiological jaundiceis due to increase in levels of indirect bilirubin. Both conjugated and unconjugated bilirubin are increased in hepatocellular diseases such as hepatitis and space-occupying lesions of the liver, bstructive lesions such as carcinoma of the head of the pancreas, common bile duct, or ampulla of Vater."

#### SGOT / AST

Clinical Significance: "Elevated aspartate aminotransferase (AST) values are seen most commonly in parenchymal liver diseases. Values can be elevated from 10 to 100 times the normal range, though commonly 20 to 50 times elevations are seen. AST levels are raised in infectious hepatitis and other inflammatory conditions





: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Sample Collected Date

Registration Date : 13/Mar/2024 12:59PM

: 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name Result Unit Bio. Ref. Range Method

affecting the liver along with ALT, though ALT levels are higher. The ALT:AST ratio which is normally 1. AST levels are usually raised before clinical signs and symptoms of disease appear. AST and ALT also rise in primary or metastatic carcinoma of the liver, with AST usually being higher than ALT. Elevated AST values may also be seen in disorders affecting the heart, skeletal muscle and kidney, such as myocardial infarction, muscular dystrophy, dermatomyositis, acute pancreatitis and crushed muscle injuries."

#### SGPT/ALT

Referred BY

Clinical Significance: Elevated alanine aminotransferase (ALT) values are seen in parenchymal liver diseases characterized by a destruction of hepatocytes. Values are at least 10 times higher the normal range and may reach up to 100 times the upper reference limit. Commonly, values are seen to be 20 - 50 times higher than normal. In infectious hepatitis and other inflammatory conditions affecting the liver, ALT levels rise more than aspartate aminotransferase (AST), and the ALT/AST ratio, which is normally 1. ALT levels usually rise before clinical signs and symptoms of disease appear.

#### Alkaline Phosphatase (ALP)

Clinical Significance: Alkaline Phosphatase levels can be elevated in both liver related as well as bone related conditions. ALP levels are raised (more than 3 fold) in extrahepatic biliary obstruction (eg, by stone or by cancer of the head of the pancreas) than in intrahepatic obstruction, and isdirectly proportional to the level of obstruction. Levels may rise up to 10 to 12 times the upper limit of normal range and returns to normal on surgical removal of the obstruction. ALP levels rise together with GGT levels and If both GGT and ALP are elevated, a liver source of the ALP is likely. Among bone diseases, ALP levels rise in Paget disease (up to 25 fold), osteomalacia, rickets, primary and secondary hyperparathyroidism and osteogenic bone cancer. Elevated ALP is seen in children following accelerated bone growth. Also, a 2 to 3fold elevation may be observed in women in the third trimester of pregnancy, although the interval is very wide and levels may not exceed the upper limit of the reference interval in some cases.

#### **Total Protein**

Clinical Significance: High levels of Serum Total Protein is seen in increased acute phase reactants in inflammation, late-stage liver disease, infections, multiple myeloma and other malignant paraproteinemias.n. Hypoproteinemia is seen in hypogammaglobulinemia, nephrotic syndrome and protein-losing enteropathy.

#### Albumin

Clinical Significance: "Hypoalbuminemia can be caused by impaired synthesis due to liver disease (primary) or due to diminished protein intake (secondary), increased catabolism due to tissue damage and inflammation; malabsorption of amino acids; and increased renal excretion (eg, nephrotic syndrome). Hyperalbuminemia is seen in dehydration."





Patient NAME

: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo

: DPL22065

Referred BY

: SELF

Refer Lab/Hosp

: APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE				
TOTAL CHOLESTEROL	147.00	mg/dL	Desirable: <= 200 Borderline High: 201-239 High:>239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.	Serum, Cholesterol oxidase esterase, peroxidase
TRIGLYCERIDES	106.50	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	Serum, Enzymatic, endpoint
H D L CHOLESTEROL	59.30	mg/dL	Normal: > 40 Major Heart Risk: < 40	Serum, Direct measure-PEG
L D L CHOLESTEROL	66.40	mg/dL	Optimal: < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190	Serum
NON HDL CHOLESTEROL	87.7	mg/dL	Desirable: < 130 mg/dL Borderline High: 130- 159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL	Calculated
VLDL	21.3	mg/dL	6 - 38	Calculated
T. CHOLESTEROL/ HDL RATIO	2.48	Ratio	3.5 - 5.0	Calculated
LDL / HDL RATIO	1.12	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - >6.0 Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	Calculated
HDL/LDL RATIO	0.89	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0 Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	Calculated





: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065 Referred BY

Refer Lab/Hosp : APOLLO CLINIC Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# **DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2**

**Test Name** Unit Bio. Ref. Range Method Result





Patient NAME

: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo

: DPL22065

Referred BY

: SELF

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:05PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C				
Sample Type: WHOLE BLOOD EDTA				
HBA1c	6.4	%	Non-Diabetic: <=6.0 Pre Diabetic:6.1 - 7.0 Diabetic: >=7.0	EDTA Whole blood,HPLC
ESTIMATED AVG. GLUCOSE	136.98	mg/dL		

### **Interpretations**

- 1. HbA1C has been endorsed by clinical groups and American Diabetes Association guidelines 2017 for diagnosing diabetes using a cut off point of 6.5%
- Low glycated haemoglobin in a non diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia (especially severe iron deficiency and haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
- 3. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control.
- Excellent control-6-7 %
- Fair to Good control 7-8 %
- Unsatisfactory control 8 to 10 %
- Poor Control More than 10 %





Patient NAME

: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo Referred BY : DPL22065

Refer Lab/Hosp

: SELF : APOLLO CLINIC Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:05PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name Result Unit Bio. Ref. Range Method

**GLUCOSE - FASTING** 

Sample Type: FLOURIDE PLASMA

Plasma Glucose Fasting 104.4 mg/dL Normal: 70-100 Plasma, Hexokinase

Impaired Fasting Glucose (IFG): 100-125

Diabetes Mellitus: >= 126 (On more than one occasion)

Note:

As per American Diabetic Association, (ADA) 2018 Guidelines:

Fasting Plasma Glucose Value (in mg/dl) Interpretation

- 70 100 Normal
- 101 125 IFG (Impaired Fasting Glucose)
- >/= 126 Diabetes mellitus

It is recommended that fasting plasma glucose be repeated on Two separate occasions or fasting plasma glucose with HbA1c should be done to confirm the diagnosis of Diabetes mellitus.

Fasting is defined as no caloric intake for at least 8 hours





Oxidase/Peroxidase

Patient NAME

: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo

: DPL22065

Referred BY

: SELF

Refer Lab/Hosp : APOLLO CLINIC Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:05PM

# DEPARTMENT OF BIOCHEMISTRY **APOLLO PACKAGE 2**

**Test Name** Result Unit Bio. Ref. Range Method Sample Type: FLOURIDE PLASMA (PP) mg/dl Plasma Glucose PP 87.3 80-140 Glucose

#### **INTERPRETATION:**

#### Increased In

**GLUCOSE - PP** 

- Diabetes Mellitus
- Stress (e.g., emotion, burns, shock, anesthesia)
- Acute pancreatitis
- Chronic pancreatitis
- Wernicke encephalopathy (vitamin B1 deficiency)
- Effect of drugs (e.g. corticosteroids, estrogens, alcohol, phenytoin, thiazides)

### Decreased In

- Pancreatic disorders
- Extrapancreatic tumors
- Endocrine disorders
- Malnutrition
- Hypothalamic lesions
- Alcoholism
- Endocrine disorders



MBBS, DNB Pathology Sr. Consultant (HMC.9669)



: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065

Referred BY

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

APOLLO PACKAGE Z							
Result	Unit	Bio. Ref. Range	Method				
19.20	mg/dL	17- 43	Urease GLDH				
8.97	mg/dL	7 - 18	Urease				
7.10	mg/dL	3.5 - 7.2	Uricase/POD				
0.80	mg/dL	0.67 - 1.17	Jaffe IDMS				
8.80	mg/dL	8.8 - 10.6	Arsenazo III				
136.2	mmol/L	136 - 146	ISE				
4.01	mmol/L	3.5 - 5.1	ISE				
102.5	mmol/L	101 - 109	ISE				
	19.20 8.97 7.10 0.80 8.80 136.2 4.01	19.20 mg/dL 8.97 mg/dL 7.10 mg/dL 0.80 mg/dL 8.80 mg/dL 136.2 mmol/L 4.01 mmol/L	Result         Unit         Bio. Ref. Range           19.20         mg/dL         17- 43           8.97         mg/dL         7 - 18           7.10         mg/dL         3.5 - 7.2           0.80         mg/dL         0.67 - 1.17           8.80         mg/dL         8.8 - 10.6           136.2         mmol/L         136 - 146           4.01         mmol/L         3.5 - 5.1				

#### Note:

## **Blood Urea Nitrogen (BUN)**

Clinical Significance: Increased blood urea nitrogen (BUN) may be due to prerenal causes (cardiac decompensation, water depletion due to decreased intake and excessive loss, increased protein catabolism, and high protein diet), renal causes (acute glomerulonephritis, chronic nephritis, polycystic kidney disease, nephrosclerosis, and tubular necrosis) and postrenal causes (eg, all types of obstruction of the urinary tract, such as stones, enlarged prostate gland, tumors).

### **Creatinine**

Clinical Significance : Serum creatinine is inversely correlated with glomerular filtration rate (GFR). Increased levels of Serum Creatinine is associated with renal dysfunction.

#### Calcium

Serum Calcium levels are used to monitor and diagnose a wide range of diseases of bone, kidney, parathyroid gland, or gastrointestinal tract. Calcium levels may also reflect abnormal vitamin D or protein levels. Hypocalcemia or low serum calcium levels is associated with absent or decreased function of the parathyroid glands, impaired vitamin-D synthesis, low dietary intake and chronic renal failure. Hypercalcemia is due to increased mobilization of calcium from the skeletal system or increased intestinal absorption. It is usually seen in case of primary hyperparathyroidism (pHPT) or bone metastasis of carcinoma of the breast, prostate, thyroid gland, or lung.

## **Sodium**

Clinical Significance: Serum Sodium estimation is performed to assess acid-base balance, water balance, water intoxication, and dehydration.

## **Potassium**



Dr. Sarita Prasad MBBS, DNB Pathology Sr. Consultant (HMC.9669)

email: sonna.road@apolloclinic.com | Online : www.apolloclinic.com



: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name Result Unit Bio. Ref. Range Method

Clinical Significance: Potassium (K+) is the major intracellular cation. It regulates neuromuscular excitability, heart contractility, intracellular fluid volume, and hydrogen ion concentration. High levels of serum Potassium is seen in acute renal disease and end-stage renal failure due to decreased excretion. Levels are also high during the diuretic phase of acute tubular necrosis, during administration of non-potassium sparing diuretic therapy, and during states of excess mineralocorticoid or glucocorticoid.

#### **Chloride**

Referred BY

Clinical Significance: Chloride (Cl) is the major extracellular anion and it has an important role in maintaining proper body water distribution, osmotic pressure, and normalanion-cation balance in the extracellular fluid compartment. Chloride is increased in dehydration, renal tubular acidosis, acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Hyperchloremia acidosis may be a sign of severe renal tubular pathology. Chloride is decreased inoverhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisonian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting, aldosteronism, bromide intoxication, syndrome of inappropriate antidiuretic hormone secretion, and conditions associated with expansion of extracellular fluid volume."





: SELF

Age/Gender :  $58 \ Y \ O \ M \ O \ D \ /M$ 

LabNo : DPL22065

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM Report Generated Date : 13/Mar/2024 02:19PM

# DEPARTMENT OF HORMONE ASSAYS APOLLO PACKAGE 2

	Test Name	Result	Unit	Bio. Ref. Range	Method	
THYROID PROFILE (T3,T4,TSH)						
Sample Type : SE	ERUM					
T3		1.38	ng/mL	0.79 - 1.58	CLIA	
T4		8.62	μg/dl	4.9 - 11.00	CLIA	
TSH		2.40	μIU/m	0.38 - 4.31	FIA	

# Interpretation

Referred BY

It is recommended to interpret serum TSH levels with thyroid hormone levels (especially T4 levels) taking into consideration the clinical status of patient. Pitfalls in the interpretation of the serum TSH alone are in patients with recent treatment for thyrotoxicosis, non-thyroidal illness(acute severe illness or chronic illness), central hypothyroidism, confounding medications.

Condition	TSH	T4	T3
Primary Hypothyroidism	Increased	Low	Normal /Low
Subclinical Hypothyroidism	Increased	Normal	Normal
Primary Hyperthyroidism	Decreased	Increased	Increased
T3 Toxicosis	Decreased	Normal	Increased
Subclinical Hyperthyroidism	Decreased	Normal	Normal
Central Hyperthyroidism/ Thyroid Hormone Resistance	Increased /Normal	Increased	Increased
Central Hypothyroidism / Non Thyroidal Illness	Decreased /Normal	Decreased	Decreased





Patient NAME

: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo Referred BY : DPL22065

Refer Lab/Hosp

: SELF

: APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:14PM

# DEPARTMENT OF HORMONE ASSAYS APOLLO PACKAGE 2

Test Name	Result	Unit	Bio. Ref. Range	Method
PROSTATE SPECIFIC ANTIGEN (PSA) - TOTAL PROSTATE SPECIFIC ANTIGEN	1.4	ng/mL	0-4	CLIA

### INTERPRETATION:

Raised Total PSA levels may indicate prostate cancer, benign prostate hypertation (BPH), or inflammation of the prostate. Prostate manipulation by biopsy or rigorous physical activity may temporarily elevate PSA levels. The blood test should be done before surgery or six weeks after manipulation. The total PSA may be ordered at regular intervals during treatment of men who have been diagnosed with Prostate cancer and in prostatic cancer cases under observation.





: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065 Referred BY


Refer Lab/Hosp : APOLLO CLINIC Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 03:35PM

# **DEPARTMENT OF CLINICAL PATHOLOGY APOLLO PACKAGE 2**

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE ROUTINE EXAMINATION				
VOLUME	30	ml	-	
COLOUR	PALE YELLOW		PALE YELLOW	
TRANSPARENCY	CLEAR		Clear	
REACTION (PH)	7.00		4.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.010 - 1.030	
CHEMICAL EXAMINATION				
URINE SUGAR.	ABSENT		Nill	
Urine Protein	ABSENT		Nil	
Urine Ketones	ABSENT		Nil	
BLOOD	ABSENT		Absent	
Leukocyte esterase	TRACE		Negative	
Bile pigments	ABSENT		Absent	
NITRITE	ABSENT	Negative		
UROBILINOGEN	ABSENT		Normal	
MICROSCOPIC EXAMINATION				
PUS CELLS	3-4	/hpf	0 - 5	
EPITHELIAL CELLS	1-2	/hpf	0 - 5	
RBCs	ABSENT	/hpf	Absent	
CRYSTALS	ABSENT		Absent	
CASTS	ABSENT		Absent	
OTHER	ABSENT			





Customer Pending Tests Mr. Parmod Vats USG pending

# **Final Bill**

Name: Mr. Pramod VatsaBill No: FSOH-OCR-958Age/Gender: 58 Y MBill/Reg Date: 13.03.2024 11:32

Contact No : +919811350753 Referal Doctor: SELF
Address : 3171 2nd Floor Sector 46 Center : Sohna Road


Corporate Name : ARCOFEMI HEALTHCARE LIMITED


Plan : ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN INDIA OP AGREEMENT

#	Department	Description Of Service	SAC Code Qty	Rate	Amount I	Discount N	let Value
1	Lab Tests	HAEMOGRAM	1	-0.01	-0.01	0.00	-0.01
2	Lab Tests	PERIPHERAL SMEAR	1	0.00	0.00	0.00	0.00
3	Lab Tests	BLOOD GROUP AND RH TYPE	1	0.00	0.00	0.00	0.00
4	Service	BODY MASS INDEX	1	0.37	0.37	0.00	0.37
5	Lab Tests	LDL CHOLESTEROL: LIPID PROFILE PACKAGE	1	0.00	0.00	0.00	0.00
6	Lab Tests	HDL CHOLESTEROL: LIPID PROFILE PACKAGE	1	0.00	0.00	0.00	0.00
7	Lab Tests	TRIGLYCERIDES: LIPID PROFILE PACKAGE	1	0.00	0.00	0.00	0.00
8	Lab Tests	VLDL CHOLESTEROL: LIPID PROFILE PACKAGE	1	0.00	0.00	0.00	0.00
9	Lab Tests	CHOLESTEROL: LIPID PROFILE PACKAGE	1	55.64	55.64	0.00	55.64
10	Lab Tests	UREA: KFT - RENAL FUNCTION TEST (BASIC)	1	0.00	0.00	0.00	0.00
11	Lab Tests	CREATININE: KFT - RENAL FUNCTION TEST (BASIC)	1	18.55	18.55	0.00	18.55
12	Lab Tests	URIC ACID: KFT - RENAL FUNCTION TEST (BASIC)	1	0.00	0.00	0.00	0.00
13	Lab Tests	BLOOD UREA NITROGEN(BUN): KFT - RENAL FUNCTION TEST (BASIC)	1	0.00	0.00	0.00	0.00
14	Lab Tests	LIVER FUNCTION TEST (PACKAGE)	1	296.73	296.73	0.00	296.73
15	Lab Tests	GGTP: GAMMA GLUTAMYL TRANSPEPTIDASE	1	74.18	74.18	0.00	74.18
16	Service FITNESS BY	ECG	1	111.27	111.27	0.00	111.27
17	GENERAL PHYSICIAN	doctor	1	0.00	0.00	0.00	0.00
18	Opthal Consultation	doctor	1	0.00	0.00	0.00	0.00
	Lab Tests	URINE ROUTINE EXAMINATION	1	0.00	0.00	0.00	0.00
	Radiology Tests	X-RAY CHEST PA	1		148.36	0.00	148.36
	Radiology Tests	ULTRASOUND WHOLE ABDOMEN	1		556.36	0.00	556.36
22	<b>DENTAL Consultation</b>		1	0.00	0.00	0.00	0.00
	ENT Consultation	doctor	1		0.00	0.00	0.00
	Diet Consultation	doctor	1	0.00	0.00	0.00	0.00
	Lab Tests	GLYCOSYLATED HEMOGLOBIN (HBA1C)	1	0.00	0.00	0.00	0.00
26	Lab Tests	THYROID PROFILE - I(T3,T4 AND TSH)	1	0.00	0.00	0.00	0.00
27	Lab Tests	GLUCOSE - (FASTING)	1	0.00	0.00	0.00	0.00
28	Lab Tests	GLUCOSE - (POST PRÁNDIAL)	1	0.00	0.00	0.00	0.00
29	Lab Tests	URINE GLUCOSE(FASTING)	1	0.00	0.00	0.00	0.00
30	Lab Tests	URINE GLUCOSE(POST PRANDIAL)	1	0.00	0.00	0.00	0.00
31	Service	2D ECHO	1	741.82	741.82	0.00	741.82

32 Lab Tests	PSA TOTAL ARCOFEMI - MEDIWHEEL - FULL	1	296.73	296.73	0.00	296.73
33 Package Charges	BODY ANNUAL PLUS ABOVE 50Y MALE - 2D ECHO - PAN INDIA - FY2324	1	0.00	0.00	0.00	0.00
				Bill Amo	ount:	2,300.00
			Т	otal Disco	ount:	0.00
				Net Payn	nent:	0.00
			C	Corporate	Due:	2,300.00
			Pri	. Sponsor		2,300.00
				Pri. Spons		0.00
				Pri. Spons		2,300.00
			Deductions	(Patient A	(mount	0.00
			Less	s Deposits	Set Off	0.00
			Less Re	eward Poin	nts Amt.	0.00
			Less	Patient Pa	yments	0.00

Authorized Signature :(Pankaj Kushwaha)







DATE- 13/03/24

NAME - PRAMOD VATICA

AGE/GENDER - S8 /MALE

EMAIL -

PHONE - 9811300753

ADDRESS - HOUSE NO 3171 / 2 nation

**CORPORATE NAME -**

1. Past medical history & medications:-

·DUT

2. Any existing disease: -

HIGH BP

3. Current medications :-

- 4. **VITALS** (To be filled by medical personnel)
  - BLOOD PRESSURE 115/82 Mmg PULSE RATE 644

  - TEMPERATURE 97 SC
  - · SPO2 9.8.1.
  - BLOOD SUGAR (RANDOM) ......
  - · HEIGHT 174 cm.
  - WEIGHT ...... 6 K.9.
  - · BMI 24.3

VISION- RE-6/20

LE-6/22

Colores vision- Normal.



# 5. FINDINGS: -

LABINVESTIGATION: - All given invertigations Normal.

CARDIOLOGY INVESTIGATIONS: - ECG - Normal

2D Echo- Normal

RADIOLOGY INVESTIGATIONS: - CXR- few small calcified Hilas Nodes.

6: DOCTOR REMARKS: -

None.





# **ECHOCARDIOGRAPHY REPORT**

Patient's Name	MR PRAMOD VATSA	Date	13-03-2024
Referred by	HEALTH CHECK UP	Age &Sex	58Yrs/M

#### MITRAL VALVE

Morphology AML - Normal / Thickening/Calcification/ Flutter/ Vegetation/ Prolapse/ SAM/ Doming

PML - Normal/ Thickening/ Calcification/ Mild Prolapse/ Paradoxical motion/ fixed.

Sub valvular deformity Present/ Absent

Score: ....

Doppler

Normal/Abnormal

A>E

Mitral Stenosis

Present/Absent

RR interval.....msec MVA......cm<sup>2</sup>

EDG.....mmHg Mitral Regurgitation

MDG.....mmHg Absent /Trivial/Mild/Moderate/Severe

#### TRICUSPID VALVE

Morphology

Normal/ Atresia/Thickening/ Calcification/ Prolapse/ Vegetation/ Doming

Doppler

Normal/ Abnormal Tricuspid Stenosis

Present/ Absent

RR interval.....

EDG.....mmHg

MDG.....mmHg

Tricuspid Regurgitation: Absent/ Trivial/ Mild/ Moderate/ Severe Fragmented signals

Velocity.....m/sec

#### **PULMONARY VALVE**

Morphology

Normal/ Atresia/ Thickening/ Doming/ Vegetation

Doppler

Normal/ Abnormal Pulmonary Stenosis

Present/Absent

Level Valvular and Sub valvular

PV Max = 1.1 m/sec

PSG.....mmHg Pulmonary annulus.....mm

Pulmonary Regurgitation

Present/ Absent

Early diastolic gradient.....mmHg. End Diastolic Gradient.....mmHg

### **AORTIC VALVE**

Morphology

Normal/ Thickening/ Tip Calcification/ Restricted Opening/ Flutter vegetation

No. of cusps

1/2/3/4

Doppler

Normal/ Abnormal

Aortic Stenosis: Present/Absent

AV Max = 1.47 m/sec

Aortic Annulus.....mm

Aertic Regurgitation

Absent/ Trivial/ Mild/Moderate/ Severe

TO BOOK AN APPOINTMENT 08079 83838 08079



Measurements	Normal Values	Measurements	<u>Normal Values</u> Sohna Road
Aorta- 2.7 LVes- 2.6 IVSed-1.0 RV ed LVVd (ml)	(2.0-3.7 cm) (2.2-4.0 cm) (0.6-1.1 cm) (0.7-2.6 cm)	LAes- 3.5 LVed- 4.1 PW (LV) 0.7 RV anterior wall LVVs (ml)	(1.9-4.0 cm) (3.7-5.6 cm) (0.6-1.1 cm) (up to 5 mm)
EF <b>60-65</b> %	(54%-76%)	IVS motion	Normal/ Flat/ Paradoxical

## CHAMBERS:

LV <u>Normal</u> / Enlarged/ Clear/ Thrombus/hypertrophy Contraction <u>Normal</u> / Reduced

LA <u>Normal</u>/ Enlarged/ <u>Clear</u>/ Thrombus

RA <u>Normal</u>/ Enlarged/ <u>Clear</u>/ Thrombus

RV <u>Normal/</u> Enlarged/ <u>Clear/</u> Thrombus

Pericardium Normal/ Thickening/ Calcification/ Effusion

# COMMENTS AND SUMMARY


- ALL FOUR CHAMBERS NORMAL IS SIZE AND SHAPE
- ALL FOUR VALVES NORMAL IN MORPHOLOGY
- NO MR/AR/TR
- NO AORTIC STENOSIS
- NORMAL LV DIASTOLIC FUNCTION
- NO CLOT/MASS/PE SEEN
- NORMAL LV SYSTOLIC FUNCTION, LVEF= 60-65%

Kindly correlate clinically


DR. RÖHIT GOEL M.D, D.M (Cardiology)

TO BOOK AN APPOINTMENT

© © 08079 838383 © 08079 848484







LP 25Hz, AC 60Hz Page 1 of 1	Part No.2.157048M (€ 0123	D 0 1 + + 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1		Printed on 13.03.2024 09:26	Print			25 mm/s, 10 mm/mV AT-102 G2 1:2.0 (1080.009830)	25 mm AT-102 G2
									=
LP 25Hz. AC 60Hz	• •			Sequential				25 mm/s, 10 mm/mV	25 mm
		V6 V		\$ 55		aVF	Away		<b>≡</b>
		V5 VS		\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		aVL			=
		V4		\frac{1}{2}		aVR			-
	elevation)	Sinus rhythm  Normal electrical axis  Nonspecific ST abnormality (elevation)  Otherwise normal ECG  Unconfirmed report	1051 ms 98 ms 146 ms 95 ms 402 ms 392 ms	57 bpm RR PR O QRS 15 47 QT C8 Otherwise normal	HR 57 Paxis ORS axis Taxis	•	Visit ID Room Medication Order ID Ord. prov. Ord. prot.	Male  Undefined  Unknown	Date of birth Gender Height Weight Ethnicity Pacemaker Indication Remark
				12-Lead	Standard 12-Lead			) Parmod vats	Patient ID



Patient's Name:-

MR. PARMOD

**VATS** 

:- 13/03/2024

Referred By :-

**HEALTH CHEAKUP** 

Age/Sex :- 58Y/M

# Radiograph of Chest (PA View)

Prominent broncho vascular marking are seen in bilateral lung fields.

Prominence bilateral hila are seen with few small calcified hilar lymph nodes.

Both CP Angle are clear.

Domes are normally placed.

Cardiac shadow appears normal.

Trachea and mediastinum are normal.

Mild degenerative changes are seen in visualised spine..

Please correlate clinically

Dr Arushi Gupta

MBBS, DNB (Radio - Diagnosis)

Radiologist



# CERTIFICATE OF MEDICAL FITNESS

e/she	: 15		I
•	Medically Fit		
0	Fit with restrictions/recommend	dations	
	Though following restrictions impediments to the job.	nave been revealed, in my opinion, these are not	
	1		
	2		
	3		
	However the employee should communicated to him/her.	follow the advice/medication that has been	
	Review after	continued to the first the desired to the second to the se	
0	Currently Unfit. Review after	recommended	
٠	Unfit		

This certificate is not meant for medico-legal purposes

## DR. BINDU BISHT

B.D.S, MIDA, MISDT (General Dentist)



NAME:- Promod vats AGE/SEX: S8/M DATE: March 13/24,

((( ) Through health checkers.

O/E > chr. gen. Shaphishs. 7 local bad pertubble

curvical abrasian, 1x multiple

+ecth:

Admice. = > Clusted Stelling.

> Scaling of Jolishing.

Balakh



Age/Gender : 58 Y O M O D /M

: SELF

LabNo : DPL22065

Referred BY

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:50PM

# DEPARTMENT OF HAEMATOLOGY APOLLO PACKAGE 2

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE BLOOD COUNT				
Sample Type: WHOLE BLOOD EDTA				
HAEMOGLOBIN (HB)	14.40	gm/dL	13.5 - 18.0	Cynmeth Photometric Measurement
RBC COUNT(RED BLOOD CELL COUNT)	4.6	mil/cu.mm	4.7 - 6.0	Electrical Impedence
PCV/HAEMATOCRIT	42.7	%	42-52	Calculated
MCV	93.30	fL	78-100	Electrical Impedence
MCH	31.5	pg	27-31	Calculated
MCHC	33.7	gm/dL	32-36	Calculated
RDW-SD	13.0	fL	39-46	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	4780	cell/cmm	4000-10000	Electrical Impedence
NEUTROPHIL	50	%	40-80	VCSn Technology
LYMPHOCYTE	37	%	20-40	VCSn Technology
MONOCYTE	10	%	2-10	VCSn Technology
EOSINOPHIL	03	%	1-6	VCSn Technology
BASOPHIL	00	%	0-2	VCSn Technology
PLATELET COUNT	182	10^3/ul	150 - 450	Electrical Impedence
MPV	11.7	fL	7.2 - 11.7	Electrical Impedence
PCT	0.2	%	0.2 - 0.5	Calculated
PDW	14.1	%	9.0 - 17.0	Calculated
ABSOLUTE NEUTROPHIL COUNT	2.39	x10^3 Cells/uL	1.5-7.8	<b>Automated Calculated</b>
ABSOLUTE LYMPHOCYTE COUNT	1.77	x10^3 Cells/uL	2.0-3.9	<b>Automated Calculated</b>
ABSOLUTE MONOCYTE COUNT	0.48	x10^3 Cells/uL	0.2-0.95	<b>Automated Calculated</b>
ABSOLUTE EOSINOPHIL COUNT	0.14	x10^3 Cells/uL	0.2-0.5	<b>Automated Calculated</b>

Tests done on Automated Three Part Cell Counter. (WBC, RBC,Platelet count by impedance method, colorimetric method for Hemoglobin, WBC differential by flow cytometry using laser technology other parameters are calculated). All Abnormal Haemograms are reviewed confirmed microscopically.





: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo Referred BY : DPL22065

Refer Lab/Hosp

: SELF : APOLLO CLINIC Barcode NO

: 20010614

Registration Date

: 13/Mar/2024 12:59PM

Sample Collected Date

: 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:50PM

# DEPARTMENT OF HAEMATOLOGY APOLLO PACKAGE 2

Test Name	Result	Unit	Bio. Ref. Range	Method
ERYTHROCYTE SEDIMENTATION RATE				
Sample Type: WHOLE BLOOD EDTA				
ERYTHROCYTE SEDIMENTATION RATE	19	mm/hr	<20	EDTA Whole blood, modified westerngren

### Note:

- 1. Test conducted on EDTA whole blood at 37°C.
- 2. ESR readings are auto- corrected with respect to Hematocrit (PCV) values.
- 3. It indicates presence and intensity of an inflammatory process. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, acute rheumatic fever. It is also increased in multiple myeloma, hypothyroidism.





: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo

: DPL22065

Referred BY Refer Lab/Hosp : SELF

: APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 03:35PM

## DEPARTMENT OF HAEMATOLOGY APOLLO PACKAGE 2

Test Name

Result

Unit

Bio. Ref. Range

Method

**BLOOD GROUP ABO & RH** 

Sample Type: WHOLE BLOOD EDTA

ABO

"B"

Gel Columns agglutination

POSITIVE

Gel agglutination

COMMENTS:

Rh Typing

The test will detect common blood grouping system A, B, O, AB and Rhesus (RhD). Unusual blood groups or rare subtypes will not be detected by this method. Further investigation by a blood transfusion laboratory, will be necessary to identify such groups.

**Disclaimer:** There is no trackable record of previous ABO & RH test for this patient in this lab. Please correlate with previous blood group findings.





: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065

Referred BY

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

	AI OLEO I ACIANCE Z							
Test Name	Result	Unit	Bio. Ref. Range	Method				
LIVER FUNCTION TEST								
Sample Type : SERUM								
TOTAL BILIRUBIN	0.69	mg/dL	0.1-1.2	Jendrassik Grof				
CONJUGATED ( D. Bilirubin)	0.20	mg/dL	Adults and Children: < 0.3	Diazotization				
UNCONJUGATED (I.D. Bilirubin)	0.49	mg/dL	0.1 - 1.0	Calculated				
SGPT	21.50	U/L	< 45	UV with P5P, IFCC 37 Degree				
SGOT	20.80	U/L	< 50	UV with P5P, IFCC 37 degree				
SGOT/SGPT	0.97	Ratio	0.7 - 1.4	· ·				
GGT	22	U/L	< 55	G-glutamyl-carboxy- nitoanilide				
ALKALINE PHOSPHATASE	89.00	U/L	56-119	PNPP, AMP Buffer, IFCC 37 degree				
TOTAL PROTEINS	7.20	g/dL	6.6-8.3	Biuret, reagent blank end point				
ALBUMIN	4.10	g/dL	Adults: 3.5 - 5.2	Bromcresol purple				
GLOBULIN	3.1	g/dL	1.8 - 3.6	Calculated				
A/G RATIO	1.32	Ratio	1.2 - 2.2	Calculated				

#### Note:

#### **Bilirubin Total**

Clinical Significance: "Total Bilirubin is one of the most commonly used tests to assess liver function. A number of inherited and acquired diseases affect bilirubin production, metabolism, storage and excretion and causes hyperbilirubinemia resulting in jaundice. Hyperbilirubinemia may be due to increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Unconjugated hyperbilirubinemia is seen in newborn andd known as physiological jaundice. Elevated unconjugated bilirubin in the neonatal period may result in brain damage (kernicterus). Crigler-Najjar syndromes type I and type II are also associated with elevated levels of indirect bilirubin. Both conjugated and unconjugated bilirubin are increased in hepatitis and space-occupying lesions of the liver; and obstructive lesions such as carcinoma of the head of the pancreas, common bile duct, or ampulla of Vater."

### **Bilirubin Direct**

Clinical Significance: "Direct bilirubin is a measurement of conjugated bilirubin. Jaundice can occur as a result of increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Inherited disorders in which direct bilirubin levels are increased are seen in Dubin-Johnson syndrome and Rotor syndrome, idiopathic neonatal hepatitis and biliary atresia. The most commonly occurring form of jaundice of the newborn called physiological jaundiceis due to increase in levels of indirect bilirubin. Both conjugated and unconjugated bilirubin are increased in hepatocellular diseases such as hepatitis and space-occupying lesions of the liver, bstructive lesions such as carcinoma of the head of the pancreas, common bile duct, or ampulla of Vater."

### SGOT / AST

Clinical Significance: "Elevated aspartate aminotransferase (AST) values are seen most commonly in parenchymal liver diseases. Values can be elevated from 10 to 100 times the normal range, though commonly 20 to 50 times elevations are seen. AST levels are raised in infectious hepatitis and other inflammatory conditions





: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Sample Collected Date

Registration Date : 13/Mar/2024 12:59PM

: 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name Result Unit Bio. Ref. Range Method

affecting the liver along with ALT, though ALT levels are higher. The ALT:AST ratio which is normally 1. AST levels are usually raised before clinical signs and symptoms of disease appear. AST and ALT also rise in primary or metastatic carcinoma of the liver, with AST usually being higher than ALT. Elevated AST values may also be seen in disorders affecting the heart, skeletal muscle and kidney, such as myocardial infarction, muscular dystrophy, dermatomyositis, acute pancreatitis and crushed muscle injuries."

#### SGPT/ALT

Referred BY

Clinical Significance: Elevated alanine aminotransferase (ALT) values are seen in parenchymal liver diseases characterized by a destruction of hepatocytes. Values are at least 10 times higher the normal range and may reach up to 100 times the upper reference limit. Commonly, values are seen to be 20 - 50 times higher than normal. In infectious hepatitis and other inflammatory conditions affecting the liver, ALT levels rise more than aspartate aminotransferase (AST), and the ALT/AST ratio, which is normally 1. ALT levels usually rise before clinical signs and symptoms of disease appear.

#### Alkaline Phosphatase (ALP)

Clinical Significance: Alkaline Phosphatase levels can be elevated in both liver related as well as bone related conditions. ALP levels are raised (more than 3 fold) in extrahepatic biliary obstruction (eg, by stone or by cancer of the head of the pancreas) than in intrahepatic obstruction, and isdirectly proportional to the level of obstruction. Levels may rise up to 10 to 12 times the upper limit of normal range and returns to normal on surgical removal of the obstruction. ALP levels rise together with GGT levels and If both GGT and ALP are elevated, a liver source of the ALP is likely. Among bone diseases, ALP levels rise in Paget disease (up to 25 fold), osteomalacia, rickets, primary and secondary hyperparathyroidism and osteogenic bone cancer. Elevated ALP is seen in children following accelerated bone growth. Also, a 2 to 3fold elevation may be observed in women in the third trimester of pregnancy, although the interval is very wide and levels may not exceed the upper limit of the reference interval in some cases.

#### **Total Protein**

Clinical Significance: High levels of Serum Total Protein is seen in increased acute phase reactants in inflammation, late-stage liver disease, infections, multiple myeloma and other malignant paraproteinemias.n. Hypoproteinemia is seen in hypogammaglobulinemia, nephrotic syndrome and protein-losing enteropathy.

### Albumin

Clinical Significance: "Hypoalbuminemia can be caused by impaired synthesis due to liver disease (primary) or due to diminished protein intake (secondary), increased catabolism due to tissue damage and inflammation; malabsorption of amino acids; and increased renal excretion (eg, nephrotic syndrome). Hyperalbuminemia is seen in dehydration."





: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo

: DPL22065

Referred BY

: SELF

Refer Lab/Hosp

: APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name	Result	Unit	Bio. Ref. Range	Method
LIPID PROFILE				
TOTAL CHOLESTEROL	147.00	mg/dL	Desirable: <= 200 Borderline High: 201-239 High:>239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.	Serum, Cholesterol oxidase esterase, peroxidase
TRIGLYCERIDES	106.50	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500	Serum, Enzymatic, endpoint
H D L CHOLESTEROL	59.30	mg/dL	Normal: > 40 Major Heart Risk: < 40	Serum, Direct measure-PEG
L D L CHOLESTEROL	66.40	mg/dL	Optimal: < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190	Serum
NON HDL CHOLESTEROL	87.7	mg/dL	Desirable: < 130 mg/dL Borderline High: 130- 159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL	Calculated
VLDL	21.3	mg/dL	6 - 38	Calculated
T. CHOLESTEROL/ HDL RATIO	2.48	Ratio	3.5 - 5.0	Calculated
LDL / HDL RATIO	1.12	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - >6.0 Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	Calculated
HDL/LDL RATIO	0.89	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0 Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0 Elevated / High risk - > 6.0	Calculated





: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065 Referred BY

Refer Lab/Hosp : APOLLO CLINIC Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

## **DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2**

**Test Name** Unit Bio. Ref. Range Method Result





: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo

: DPL22065

Referred BY

: SELF

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:05PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C				
Sample Type: WHOLE BLOOD EDTA				
HBA1c	6.4	%	Non-Diabetic: <=6.0 Pre Diabetic:6.1 - 7.0 Diabetic: >=7.0	EDTA Whole blood,HPLC
ESTIMATED AVG. GLUCOSE	136.98	mg/dL		

### **Interpretations**

- 1. HbA1C has been endorsed by clinical groups and American Diabetes Association guidelines 2017 for diagnosing diabetes using a cut off point of 6.5%
- Low glycated haemoglobin in a non diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia (especially severe iron deficiency and haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
- 3. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control.
- Excellent control-6-7 %
- Fair to Good control 7-8 %
- Unsatisfactory control 8 to 10 %
- Poor Control More than 10 %





: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo Referred BY : DPL22065

Refer Lab/Hosp

: SELF : APOLLO CLINIC Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:05PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name Result Unit Bio. Ref. Range Method

**GLUCOSE - FASTING** 

Sample Type: FLOURIDE PLASMA

Plasma Glucose Fasting 104.4 mg/dL Normal: 70-100 Plasma, Hexokinase

Impaired Fasting Glucose (IFG): 100-125

Diabetes Mellitus: >= 126 (On more than one occasion)

Note:

As per American Diabetic Association, (ADA) 2018 Guidelines:

Fasting Plasma Glucose Value (in mg/dl) Interpretation

- 70 100 Normal
- 101 125 IFG (Impaired Fasting Glucose)
- >/= 126 Diabetes mellitus

It is recommended that fasting plasma glucose be repeated on Two separate occasions or fasting plasma glucose with HbA1c should be done to confirm the diagnosis of Diabetes mellitus.

Fasting is defined as no caloric intake for at least 8 hours





Oxidase/Peroxidase

Patient NAME

: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo

: DPL22065

Referred BY

: SELF

Refer Lab/Hosp : APOLLO CLINIC Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:05PM

## DEPARTMENT OF BIOCHEMISTRY **APOLLO PACKAGE 2**

**Test Name** Result Unit Bio. Ref. Range Method Sample Type: FLOURIDE PLASMA (PP) mg/dl Plasma Glucose PP 87.3 80-140 Glucose

#### **INTERPRETATION:**

### Increased In

**GLUCOSE - PP** 

- Diabetes Mellitus
- Stress (e.g., emotion, burns, shock, anesthesia)
- Acute pancreatitis
- Chronic pancreatitis
- Wernicke encephalopathy (vitamin B1 deficiency)
- Effect of drugs (e.g. corticosteroids, estrogens, alcohol, phenytoin, thiazides)

### Decreased In

- Pancreatic disorders
- Extrapancreatic tumors
- Endocrine disorders
- Malnutrition
- Hypothalamic lesions
- Alcoholism
- Endocrine disorders



MBBS, DNB Pathology Sr. Consultant (HMC.9669)



: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065

Referred BY

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

APOLLO PACRAGE 2								
Result	Unit	Bio. Ref. Range	Method					
19.20	mg/dL	17- 43	Urease GLDH					
8.97	mg/dL	7 - 18	Urease					
7.10	mg/dL	3.5 - 7.2	Uricase/POD					
0.80	mg/dL	0.67 - 1.17	Jaffe IDMS					
8.80	mg/dL	8.8 - 10.6	Arsenazo III					
136.2	mmol/L	136 - 146	ISE					
4.01	mmol/L	3.5 - 5.1	ISE					
102.5	mmol/L	101 - 109	ISE					
	19.20 8.97 7.10 0.80 8.80 136.2 4.01	19.20 mg/dL 8.97 mg/dL 7.10 mg/dL 0.80 mg/dL 8.80 mg/dL 136.2 mmol/L 4.01 mmol/L	Result         Unit         Bio. Ref. Range           19.20         mg/dL         17- 43           8.97         mg/dL         7 - 18           7.10         mg/dL         3.5 - 7.2           0.80         mg/dL         0.67 - 1.17           8.80         mg/dL         8.8 - 10.6           136.2         mmol/L         136 - 146           4.01         mmol/L         3.5 - 5.1					

### Note:

### **Blood Urea Nitrogen (BUN)**

Clinical Significance: Increased blood urea nitrogen (BUN) may be due to prerenal causes (cardiac decompensation, water depletion due to decreased intake and excessive loss, increased protein catabolism, and high protein diet), renal causes (acute glomerulonephritis, chronic nephritis, polycystic kidney disease, nephrosclerosis, and tubular necrosis) and postrenal causes (eg, all types of obstruction of the urinary tract, such as stones, enlarged prostate gland, tumors).

### **Creatinine**

Clinical Significance : Serum creatinine is inversely correlated with glomerular filtration rate (GFR). Increased levels of Serum Creatinine is associated with renal dysfunction.

### Calcium

Serum Calcium levels are used to monitor and diagnose a wide range of diseases of bone, kidney, parathyroid gland, or gastrointestinal tract. Calcium levels may also reflect abnormal vitamin D or protein levels. Hypocalcemia or low serum calcium levels is associated with absent or decreased function of the parathyroid glands, impaired vitamin-D synthesis, low dietary intake and chronic renal failure. Hypercalcemia is due to increased mobilization of calcium from the skeletal system or increased intestinal absorption. It is usually seen in case of primary hyperparathyroidism (pHPT) or bone metastasis of carcinoma of the breast, prostate, thyroid gland, or lung.

### **Sodium**

Clinical Significance: Serum Sodium estimation is performed to assess acid-base balance, water balance, water intoxication, and dehydration.

### **Potassium**



Dr. Sarita Prasad MBBS, DNB Pathology Sr. Consultant (HMC.9669)

email: sonna.road@apolloclinic.com | Online : www.apolloclinic.com



: SELF

Age/Gender : 58 Y O M O D /M

LabNo : DPL22065

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:06PM

# DEPARTMENT OF BIOCHEMISTRY APOLLO PACKAGE 2

Test Name Result Unit Bio. Ref. Range Method

Clinical Significance: Potassium (K+) is the major intracellular cation. It regulates neuromuscular excitability, heart contractility, intracellular fluid volume, and hydrogen ion concentration. High levels of serum Potassium is seen in acute renal disease and end-stage renal failure due to decreased excretion. Levels are also high during the diuretic phase of acute tubular necrosis, during administration of non-potassium sparing diuretic therapy, and during states of excess mineralocorticoid or glucocorticoid.

#### **Chloride**

Referred BY

Clinical Significance: Chloride (Cl) is the major extracellular anion and it has an important role in maintaining proper body water distribution, osmotic pressure, and normalanion-cation balance in the extracellular fluid compartment. Chloride is increased in dehydration, renal tubular acidosis, acute renal failure, metabolic acidosis associated with prolonged diarrhea and loss of sodium bicarbonate, diabetes insipidus, adrenocortical hyperfuction, salicylate intoxication and with excessive infusion of isotonic saline or extremely high dietary intake of salt. Hyperchloremia acidosis may be a sign of severe renal tubular pathology. Chloride is decreased inoverhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis, congestive heart failure, Addisonian crisis, certain types of metabolic acidosis, persistent gastric secretion and prolonged vomiting, aldosteronism, bromide intoxication, syndrome of inappropriate antidiuretic hormone secretion, and conditions associated with expansion of extracellular fluid volume."





: SELF

Age/Gender :  $58 \ Y \ O \ M \ O \ D \ /M$ 

LabNo : DPL22065

Refer Lab/Hosp : APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM Report Generated Date : 13/Mar/2024 02:19PM

# DEPARTMENT OF HORMONE ASSAYS APOLLO PACKAGE 2

	Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFIL	E (T3,T4,TSH)				
Sample Type : SE	RUM				
T3		1.38	ng/mL	0.79 - 1.58	CLIA
T4		8.62	μg/dl	4.9 - 11.00	CLIA
TSH		2.40	μIU/m	0.38 - 4.31	FIA

## Interpretation

Referred BY

It is recommended to interpret serum TSH levels with thyroid hormone levels (especially T4 levels) taking into consideration the clinical status of patient. Pitfalls in the interpretation of the serum TSH alone are in patients with recent treatment for thyrotoxicosis, non-thyroidal illness(acute severe illness or chronic illness), central hypothyroidism, confounding medications.

Condition	TSH	<b>T4</b>	T3
Primary Hypothyroidism	Increased	Low	Normal /Low
Subclinical Hypothyroidism	Increased	Normal	Normal
Primary Hyperthyroidism	Decreased	Increased	Increased
T3 Toxicosis	Decreased	Normal	Increased
Subclinical Hyperthyroidism	Decreased	Normal	Normal
Central Hyperthyroidism/ Thyroid Hormone Resistance	Increased /Normal	Increased	Increased
Central Hypothyroidism / Non Thyroidal Illness	Decreased /Normal	Decreased	Decreased





: MR.PRAMOD VATSA

Age/Gender

: 58 Y O M O D /M

LabNo Referred BY : DPL22065

Refer Lab/Hosp

: SELF

: APOLLO CLINIC

Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM

Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 02:14PM

# DEPARTMENT OF HORMONE ASSAYS APOLLO PACKAGE 2

Test Name	Result	Unit	Bio. Ref. Range	Method
PROSTATE SPECIFIC ANTIGEN (PSA) - TOTAL PROSTATE SPECIFIC ANTIGEN	1.4	ng/mL	0-4	CLIA

### INTERPRETATION:

Raised Total PSA levels may indicate prostate cancer, benign prostate hypertation (BPH), or inflammation of the prostate. Prostate manipulation by biopsy or rigorous physical activity may temporarily elevate PSA levels. The blood test should be done before surgery or six weeks after manipulation. The total PSA may be ordered at regular intervals during treatment of men who have been diagnosed with Prostate cancer and in prostatic cancer cases under observation.





Age/Gender : 58 Y O M O D /M

: SELF

LabNo : DPL22065 Referred BY

Refer Lab/Hosp : APOLLO CLINIC Barcode NO : 20010614

Registration Date : 13/Mar/2024 12:59PM Sample Collected Date : 13/Mar/2024 12:59PM

Report Generated Date : 13/Mar/2024 03:35PM

## **DEPARTMENT OF CLINICAL PATHOLOGY APOLLO PACKAGE 2**

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE ROUTINE EXAMINATION				
VOLUME	30	ml	-	
COLOUR	PALE YELLOW		PALE YELLOW	
TRANSPARENCY	CLEAR		Clear	
REACTION (PH)	7.00		4.5 - 7.0	
SPECIFIC GRAVITY	1.010		1.010 - 1.030	
CHEMICAL EXAMINATION				
URINE SUGAR.	ABSENT		Nill	
Urine Protein	ABSENT		Nil	
Urine Ketones	ABSENT		Nil	
BLOOD	ABSENT		Absent	
Leukocyte esterase	TRACE		Negative	
Bile pigments	ABSENT		Absent	
NITRITE	ABSENT		Negative	
UROBILINOGEN	ABSENT		Normal	
MICROSCOPIC EXAMINATION				
PUS CELLS	3-4	/hpf	0 - 5	
EPITHELIAL CELLS	1-2	/hpf	0 - 5	
RBCs	ABSENT	/hpf	Absent	
CRYSTALS	ABSENT		Absent	
CASTS	ABSENT		Absent	
OTHER	ABSENT			

\*\*\* End Of Report \*\*\*

